Beinema Maarten J, de Jong Petra H, Salden Har J M, van Wijnen Merel, van der Meer Jan, Brouwers Jacobus R B J
Deventer Hospital Thrombosis Center, Deventer, The Netherlands.
Mol Diagn Ther. 2007;11(2):123-8. doi: 10.1007/BF03256232.
To determine the influence of NSAIDs on the international normalized ratio (INR) in patients with cytochrome P450 (CYP)-2C9 enzyme variants starting acenocoumarol (an oral coumarin) therapy during the first 7 days after total hip replacement surgery.
In this prospective study, an age-dependent protocol was used for the initiation of the acenocoumarol dose. Low-molecular-weight heparin was given for 5 days. The study included 100 patients undergoing total hip replacement surgery. After the inclusion of the last patient, polymerase chain reaction CYP2C9 mutation testing was performed for all patients. Drug-use evaluation of NSAIDs and other potential coumarin-drug interactions was also performed.
Eleven patients had an INR on 1 or more days >4.9. There were 52 patients who were using NSAIDs. Patients with a CYP2C9 mutation had a mean INR curve similar to patients without the mutation when NSAIDs were not coadministered. Within the group of patients heterozygous for a CYP2C9 mutation (n=30) only concomitant use of a NSAID resulted in an INR >4.9 (0% vs 38.9%, p<0.05).
In the group of patients with a CYP2C9 variant (*2 or *3 alleles), only concomitant use of a NSAID resulted in INRs >4.9. The cost effectiveness of CYP2C9 screening before elective surgery has yet to be determined.
确定非甾体抗炎药(NSAIDs)对细胞色素P450(CYP)-2C9酶变体患者在全髋关节置换术后第1天开始使用醋硝香豆素(一种口服香豆素)治疗期间国际标准化比值(INR)的影响。
在这项前瞻性研究中,采用了根据年龄制定的醋硝香豆素剂量起始方案。给予低分子量肝素5天。该研究纳入了100例行全髋关节置换术的患者。纳入最后一名患者后,对所有患者进行聚合酶链反应CYP2C9突变检测。还对NSAIDs的用药情况及其他潜在的香豆素类药物相互作用进行了评估。
11例患者在1天或更多天的INR>4.9。有52例患者使用NSAIDs。在未同时使用NSAIDs时,CYP2C9突变患者的平均INR曲线与未突变患者相似。在CYP2C9突变杂合子患者组(n = 30)中,仅同时使用NSAIDs会导致INR>4.9(0%对38.9%,p<0.05)。
在CYP2C9变体(2或3等位基因)患者组中,仅同时使用NSAIDs会导致INR>4.9。择期手术前CYP2C9筛查的成本效益尚未确定。